Alnylam Pharmace. buy Saftman
Summary
This prediction ended on 08.07.22 with a price of €149.84. The BUY prediction by Saftman finished with a performance of 2.31%. Saftman has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Alnylam Pharmace. | 0.139% | 0.139% | 21.597% | 43.179% |
iShares Core DAX® | -0.621% | 1.080% | 11.291% | 16.439% |
iShares Nasdaq 100 | -4.503% | -5.432% | 22.172% | 39.304% |
iShares Nikkei 225® | -2.562% | -1.617% | 7.262% | 8.383% |
iShares S&P 500 | -1.706% | -1.223% | 22.550% | 40.997% |
Comments by Saftman for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.